Post-doctoral position in Human Immunology Available

About the project

              The Bowdish lab has received funding from the Canadian Institute for Health Research (CIHR) to study immune responses to SARS-CoV-2 infections and vaccinations in older adults including those living in long-term care. The applicant will use over 10,000 biobanked saliva, PBMCs, and serum from over 500 participants in addition to participant metadata and detailed infection records to;

  1. Uncover novel correlates of protection in older and frail adults, including, but not limited to, ACP, ADCC, and cellular immune responses.
  2. To understand why immune responses are not always protective in older adults and may contribute to subsequent infections.

The successful applicant will have significant leeway to develop an independent research project based on their interests and expertise.  The applicant will work closely with an experienced technician and a graduate student, external collaborators, and will have access to biostatistics expertise.  If interested, there will be opportunities to teach undergraduate courses.

The initial contract will be for one year, with the possibility of extending for more years, depending on productivity. The position is funded, but the applicant will also apply for internal and external funding sources.

About the Bowdish Lab

              The Bowdish Lab is situated at Canada’s most research-intensive university, McMaster University in Hamilton, Ontario Canada. We are a diverse group of undergraduate students, graduate students, technicians and post-doctoral fellows committed to uncovering how the aging immune system changes and understanding why this alters immune responses to vaccination and respiratory infection. For more details on our lab’s philosophy see http://www.bowdish.ca/lab/lab-philosophy/ . We emphasize teamwork, career development, and leadership. Many of our former PDFs have gone on to independent faculty positions in Canada and abroad.

   
Must have;Passion for discovery & evidence of leadership in the form of first-author publications in a relevant field.Team-player with history of collaboration and mentorshipFlow cytometry experienceDeep knowledge of immunity   Nice to have;Experience in human immunology/vaccinologyExperience in antibody quantitation and functional antibody assays (e.g., ADCC, ADP)Experience in intracellular cytokine staining or Experience in science communication with vulnerable populations.

Application process

Please send Dr. Bowdish (bowdish@mcmaster.ca);

  1. A cover letter explaining your interest, skills and career goals and potential start-dates.
  2. A sample of your writing (e.g., first author publication, thesis, other)
  3. C.V.
  4. Names and email addresses of 2 references

Click here for .doc of posting

Publication: Canadian Immunity Task Force (CITF) Hema-Net Serosurveillance Meeting

Serosurveillance describes using blood samples to determine what percentage of the population has been exposed to a pathogen or has been vaccinated by measuring the presence or absence of antibodies to the pathogen or vaccination. During the COVID-19 pandemic Dr. Bowdish and team built a network of long-term care homes to measure vaccine responses and infection rates, but this infrastructure could have been used to measure virtually any infection or any antibody response. The Hema-Net community came together February 14-16 to present data and share experiences using serosurveillance and published this report. Unfortunately, no funds were made available to continue Dr. Bowdish’s or others serosurveillance networks.

See the CITF website here.

See the English report here.

See the French Report here.

Publication: “Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis”

Jenna Benoit (PhD candidate) has published her first, first author paper characterizing how immune responses to vaccination differ in people living with rheumatoid arthritis. We found some interesting new drug-immune interactions.

See the full paper here.

See thread here: https://bsky.app/profile/msmacrophage.bsky.social/post/3kh2uswvqtm2u

or below….

New paper alert! @jennabenoit.bsky.social and team studied COVID-19 vaccinations in people living with rheumatoid arthritis who are on immunosuppressive drugs and found some interesting, and to our knowledge, unknown effects of specific drugs 1/n

Almost all studies of vaccine immunogenicity (i.e., how strong an immune response is to a vaccine) focus on antibody responses. Measuring the amount of antibodies produced is cheap and (relatively) easy; however, in the Omicron-era these are less predictive of protection than you might think 2/n

When investigating anti-receptor binding domain (RBD) antibodies @jennabenoit.bsky.social and team found that -unsurprisingly- people living with RA and men had lower antibody responses (men have lower antibody responses to vaccination in general), and people with COVID had higher responses (i.e., that hybrid immunity you’ve heard so much about) 3/n

What caused these lower antibody responses? DMARDs (disease modifying anti-rheumatic drugs),and anti-TNF were not associated with lower antibody levels, the effect of steroids was not significant, but costimulation inhibitors reduced antibody levels 4/n

Important caveat: The effect of co-stimulation inhibitors was about the same as being a biologic male, so whether this reduction is associated with increased risk of infection or not is not something we can comment on 5/n.

We didn’t see an effect of drugs on neutralizing antibodies (i.e., antibodies that bind the virus really well and prevent it from entering us), but we did not have enough people on some of the drugs to really investigate this 6/n.

My favourite part: CD4+ and CD8+ T cell responses to vaccination are much, much harder to measure (each dot on the graph costs about $350 and 3+ hrs of time – hence the ‘team’ I keep mentioning) but we know that they are important for preventing infection.7/n

We found that people living with RA had lower CD4+ T cell responses (= ‘helper’ cells that support many aspects of the immune response to infection & vaccination), those who had had COVID were higher – more of that hybrid immunity you’ve heard about. 8/n

BUT even though we had a small number of people on JAK inhibitors, those who were on them had markedly lower CD4+ responses. The effect of co-stimulation inhibitors was not as apparent – but again low numbers of participants so hard to say. 9/n

Speculative side note: We use influenza vaccine as a control. Everyone has had exposure as kids so this measures a memory response made prior to having been vaccinated. Co-stim inhibitors don’t affect influenza but JAK inhibitors do – therefore no defect in pre-drug immune responses? 10/n

CD8+ T cell responses (‘killers’ of virus infected cells), were higher in men (previously known), and didn’t seem to be lower in most drugs, except maybe steroids. 11/n

Caveats: Our study was small and due to the fact we were measuring 1,2,3 doses, we were recruiting fast and furious and didn’t capture as many people on some of the drugs as we would have liked,so all results need to be replicated. 12/n

Clinical relevance: Some of these drugs are associated with increased risk of severe disease (see text for references) and by learning which aspects of the immune response they affect, we learn which aspects of the immune response are required for a successful vaccine. 13/n

Deepest appreciation for our research participants, the Canadian Arthritis Patient Alliance (see website for talks on this topic), the SUCCEED investigator team, our technical staff, fundign from the Public Health Agency of Canada, and you for reading to 14/n

Dr. Bowdish speaks about COVID-19 vaccinations to the Canadian Arthritis Patient Alliance

On November 4, 2023, the Canadian Arthritis Patient Alliance hosted an educational webinar and panel discussion about COVID-19 vaccines moderated by Dr. Dawn Richards, Vice-President with CAPA. The panel included: – Nadine Lalonde, who lives with Systemic Lupus Erythematosus and is – involved as an active patient partner on various research projects and a member of the Arthritis Patient Advisory Board with Arthritis Research Canada – Inés Colmegna is a rheumatologist, researcher and Associate Professor of Medicine at McGill University – Dawn Bowdish is a Canada Research Chair in Aging and Immunity, and Professor, McMaster University #CAPA #CanadianArthritisPatientAlliance #arthritis #rheumatoidarthritis #arthritisawareness #livingwitharthritis #ra #ramedications #managingra #earlystagesofarthritis #arthritisadvocate #arthritispatient #arthritistreatment #rheumatoid #arthritisresource #didyouknow #flares #managingflares #flaring #vaccines #covid19 #RAvaccines